Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Cornea
Share your love
EO2002: Non-Surgical Solution for Corneal Edema
Emmecell has announced positive results from its U.S. multicenter Phase 1 trial evaluating EO2002, an innovative non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in best corrected visual acuity (BCVA) and reductions in central corneal…
Strategies on How Reduce Eye Pressure Instantly
What Is Intraocular Pressure? Eye pressure, also known as intraocular pressure (IOP), is a critical factor in maintaining the health of your eyes. Elevated eye pressure can lead to various eye conditions, including glaucoma, which can result in permanent vision…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…
Innovations in Dry Eye Testing: New Diagnostic Tools
Dry eye disease (DED), also known as keratoconjunctivitis sicca, is one of the most common ophthalmic conditions, affecting hundreds of millions of people worldwide. Recent technological advances and research targeting DED have led to the emergence of new definitions and…
Link Between Proteins in Tears and Pain After Eye Surgery
In a study published in the Journal of Proteome Research, researchers from Oregon Health & Science University (OHSU) have identified a connection between specific proteins found in patients’ tears and persistent pain experienced months after eye surgery. This discovery could…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
What Is Symblepharon? | OBN
What Is Symblepharon? Symblepharon is a medical condition characterized by the adhesion of the conjunctiva, the clear membrane that covers the white part of the eye and the inside of the eyelids, to the cornea, the clear front part of…
The 40th Congress of the ESCRS | Milan 16
The 40th Congress of the ESCRS is taking place from 16-20 September 2022, at the Milano Convention Centre in Milan, Italy. The congress, which will host around 1,000 registered participants, will also be streamed via the virtual conferencing platform now…
Harrow Starts Triesence Relaunch Strategy
Harrow Pharmaceuticals announced its efforts to relaunch Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL in the United States market. The company announced the successful manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches required for the relaunch.…
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…